Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
复制标题
DOI：
10.1086/314904
复制
发表时间：
1999-08-01
影响因子：
6.4
通讯作者：
Man, CY
中科院分区：
文献类型：
--
作者：
Monto, AS;Fleming, DM;Man, CY
扎那米韦（每日2次或4次，持续5天）治疗流感感染的疗效和安全性进行了评估。共有1256名患者进入研究；其中57%的人被实验室证实感染了流感。主要终点“主要症状的缓解”是为了评估临床影响的差异。在有或没有流感感染的总体人群中，扎那米韦使达到这一终点的中位数天数减少了1天（P = 0.012 2X /天，P = 0.014 4X /天，P = 0.014 4X /天）。在症状出现30小时内治疗的患者、研究开始时发热的患者和确定的高危人群中，降低幅度更大。扎那米韦减少了睡眠紊乱的夜晚，恢复正常活动的时间，并减少了症状缓解药物的使用。这是可以忍受的。这些结果表明，扎那米韦可以显著缩短流感的持续时间和整体症状效果。
The efficacy and safety of zanamivir, administered 2X or 4X daily over 5 days, was evaluated in the treatment of influenza infections. A total of 1256 patients entered the study; 57% of those randomized had laboratory-confirmed influenza infection. The primary end point, "alleviation of major symptoms," was created to evaluate differences in clinical impact. In the overall population with or without influenza infection, zanamivir reduced the median number of days to reach this end point by 1 day (P = .012 2X daily vs, placebo; P = .014 4X daily vs. placebo). The reduction was greater in patients treated within 30 h of symptom onset, febrile at study entry, and in defined high-risk groups. Zanamivir reduced nights of disturbed sleep, time to resumption of normal activities, and use of symptom relief medications. It was well tolerated. These results suggest that zanamivir can significantly reduce the duration and overall symptomatic effect of influenza.